Wild-type (senile) amyloidosis other diagnostic studies: Difference between revisions
Line 15: | Line 15: | ||
| | | | ||
*[[Endomyocardial biopsy|Endomyocardial biopsy (EMB)]] with [[histopathology]] remains the [[Gold standard (test)|gold standard]] for [[diagnosis]] of cardiac amyloidosis. | *[[Endomyocardial biopsy|Endomyocardial biopsy (EMB)]] with [[histopathology]] remains the [[Gold standard (test)|gold standard]] for [[diagnosis]] of cardiac amyloidosis. | ||
*[[Histopathology]] demonstrates deposition of amorphous deposits of amyloid fibrils in the heart. | *[[Histopathology]] demonstrates deposition of amorphous deposits of [[amyloid]] fibrils in the [[heart]]. | ||
* The binding of Congo red stain to the deposited amyloid fibrils leads to characteristic apple-green birefringence under polarized light microscopy and an intense yellow-green fluorescence is seen when binding to thioflavin. | * The binding of [[Congo red]] [[stain]] to the deposited [[amyloid]] fibrils leads to characteristic apple-green [[birefringence]] under polarized [[light microscopy]] and an intense yellow-green [[fluorescence]] is seen when binding to [[thioflavin]]. | ||
* Precursor protein identification can be accomplished by immunohistochemistry, electron microscopy, or mass spectrometry (preferred), depending upon institutional expertise. | * Precursor [[protein]] identification can be accomplished by [[immunohistochemistry]], [[Electron microscope|electron microscopy]], or [[mass spectrometry]] (preferred), depending upon institutional expertise. | ||
* Adjunctive laboratory tests to rule out AL include assaying for other organ dysfunction (e.g., proteinuria, alkaline phosphatase) and directly measuring the circulating light chains in plasma. | * Adjunctive laboratory tests to rule out AL include assaying for other organ dysfunction (e.g., proteinuria, alkaline phosphatase) and directly measuring the circulating light chains in plasma. | ||
* EMB is associated with risks of complications such as | * EMB is associated with risks of complications such as |
Revision as of 19:07, 20 December 2019
Wild-type (senile) amyloidosis Microchapters |
Differentiating Wild-type (senile) amyloidosis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Wild-type (senile) amyloidosis other diagnostic studies On the Web |
American Roentgen Ray Society Images of Wild-type (senile) amyloidosis other diagnostic studies |
FDA on Wild-type (senile) amyloidosis other diagnostic studies |
CDC on Wild-type (senile) amyloidosis other diagnostic studies |
Wild-type (senile) amyloidosis other diagnostic studies in the news |
Blogs on Wild-type (senile) amyloidosis other diagnostic studies |
Risk calculators and risk factors for Wild-type (senile) amyloidosis other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]
Overview
Other diagnostic studies that help in diagnosing wild-type (senile) amyloidosis include histopathological analysis and genetic testing.
Other Diagnostic Studies
Other diagnostic studies that help in diagnosing wild-type (senile) amyloidosis include histopathological analysis and genetic testing.[1]
Other Diagnostic Studies | |
---|---|
Histopathological analysis |
|
Genetic testing |
|
References
- ↑ Damy T, Deux JF, Moutereau S, Guendouz S, Mohty D, Rappeneau S, Guellich A, Hittinger L, Loric S, Lefaucheur JP, Plante-Bordeneuve V (December 2013). "Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis". Amyloid. 20 (4): 212–20. doi:10.3109/13506129.2013.825240. PMID 23964755.